作者: N Knijn , L J M Mekenkamp , M Klomp , M E Vink-Börger , J Tol
DOI: 10.1038/BJC.2011.26
关键词: Oncology 、 Biopsy 、 Mutation (genetic algorithm) 、 Colorectal cancer 、 Pathology 、 Liver tumor 、 KRAS Mutation Analysis 、 Carcinoma 、 Internal medicine 、 Metastasis 、 Medicine 、 Cancer
摘要: KRAS mutation is a negative predictive factor for treatment with anti-epidermal growth receptor antibody in metastatic colorectal cancer (CRC). analysis usually performed on primary tumour tissue because often not available. However, controversial data are available the concordance of test results between tumours and corresponding metastases. We assessed status study 305 their liver Patients histologically confirmed CRC who underwent surgical resection biopsy or metastasis were included. was codons 12 13. detected 108 out (35.4%). In 11 cases (3.6%), we found discordance metastasis: 5 had wild-type metastasis, 1 wild type different mutation. observed high 96.4% (95% CI 93.6–98.2%) only six patients (2.0%; 95% 0.7–4.2%), clinically relevant. this largest most homogenous to date, conclude that both metastases can be used analysis.